Skip to content
DataLookout
Menu

NCT05617755

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 12 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Active patients have been rolled over to a separate LTFU study.
    • Eligibility criteria expanded, about 16 words
    • Study completion date changed from estimate of Feb 2027 to Oct 26, 2026
  2. Study Identification, Study Status, Oversightv12
  3. Minor Enrollment target: estimated 60 to confirmed 19
    • Study sites: 10 to 8
    v11
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2024 to Sep 30, 2024
    • Site details revised at 10 of 10 sites
    v9
  5. Notable Primary completion date: Mar 2024 to Dec 2024v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 8 to 10v7
  2. Notable Eligibility criteria expanded, about 4 words
    • Study sites: 5 to 8
    v6
  3. Minor Study sites: 2 to 5v5
  4. Minor Study sites: 1 to 2v4
  5. Minor Start date changed from estimate of Nov 2022 to Nov 29, 2022v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events and dose limiting toxicities (DLTs)
Timeframe: Up to 2 years post treatment
Maximal tolerated dose of AB-1015
Timeframe: Up to 21 days

Secondary (3)

Number of AB-1015 cells
Evidence of anti-tumor activity
Co-expression of ALPG and MSLN targets on tumor cells

Arms and interventions

AB-1015Experimental

Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.

Biologicals: AB-1015

Sites

8 sites in 1 country